Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (ω) receptor agonists on defensive behaviors of mice

Pharmacology Biochemistry and Behavior

Volumn 62, Issue 4, 1999, Pages 689-694

  Griebel, Guy ^a   Perrault, Ghislaine ^a   Sanger, David J ^a  

^a CNS Research Department   (France)

Author keywords

Anxiety; Benzodiazepines; Clobazam; Defensive behavior; Diazepam; Flight; Risk assessment; RWJ 46771; Swiss mouse; Y 23684

Indexed keywords

2 (4 CHLOROPHENYL) 5,6 DIHYDRO [1]BENZOTHIEPINO[5,4 C]PYRIDAZIN 3(2H) ONE 7 OXIDE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CLOBAZAM; DIAZEPAM; RWJ 46771; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; FLIGHT; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; TRANQUILIZING ACTIVITY;

AGGRESSION; ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BENZIMIDAZOLES; BENZODIAZEPINES; BENZOTHIEPINS; DIAZEPAM; MALE; MICE; MOTOR ACTIVITY; PYRIDAZINES; PYRIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, GABA-A; RISK-TAKING;

EID: 0032986138     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00209-3     Document Type: Article

References (24)

1. Blanchard, D. C.; Blanchard, R. J.; Rodgers, R. J.: Risk assessment and animal models of anxiety. In: Olivier, B.; Mos, J.; Slangen, J. L. eds. Animal models in Psychopharmacology. Basel: Birkhauser Verlag AG; 1991:117-134.
2. Blanchard R.J., Griebel G., Henrie J.A., Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 21:1997;783-789.
3. Blanchard R.J., Taukulis H.K., Rodgers R.J., Magee L.K., Blanchard D.C. Yohimbine potentiates active defensive responses to threatening stimuli in Swiss-Webster mice. Pharmacol. Biochem. Behav. 44:1993;673-681.
4. Blanchard R.J., Yudko E.B., Rodgers R.J., Blanchard D.C. Defense system psychopharmacology. An ethological approach to the pharmacology of fear and anxiety Behav. Brain Res. 58:1993;155-165.
5. Depoortere H., Zivkovic B., Lloyd K.G., Sanger D.J., Perrault G., Langer S.Z., Bartholini G. Zolpidem, a novel non-benzodiazepine hypnotic. I. Neuropharmacological and behavioral effects J. Pharmacol. Exp. Ther. 237:1986;649-658.
6. A receptors J. Pharmacol. Exp. Ther. 266:1993;1018-1028.
7. Griebel G., Blanchard D.C., Agnes R.S., Blanchard R.J. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berlin). 120:1995;57-66.
8. Griebel G., Blanchard D.C., Blanchard R.J. Predator-elicited flight responses in Swiss-Webster an experimental model of panic attacks. Prog. Neuropsychol. Biol. Psychol. 20:1996;185-205.
9. Griebel G., Blanchard D.C., Blanchard R.J. Evidence that the behaviors in the Mouse Defense Test Battery relate to different emotional states. A factor analytic study Physiol. Behav. 60:1996;1255-1260.
10. Griebel G., Blanchard D.C., Jung A., Blanchard R.J. A model of 'antipredator' defense in Swiss-Webster mice. Effects of benzodiazepine receptor ligands with different intrinsic activities Behav. Pharmacol. 6:1995;732-745.
11. Griebel G., Blanchard D.C., Jung A., Lee J.C., Masuda C.K., Blanchard R.J. Further evidence that the Mouse Defense Test Battery is useful for screening anxiolytic and panicolytic drugs. Effects of acute and chronic treatment with alprazolam Neuropharmacology. 34:1995;1625-1633.
12. 2A antagonist pirenperone. Pharmacol. Biochem. Behav. 51:1995;235-244.
13. Griebel G., Curet O., Perrault G., Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs. Correlation with changes in monoamine-oxidase activity and monoamine levels Neuropharmacology. 37:1998;927-935.
14. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology. 36:1997;793-802.
15. Griebel G., Sanger D.J., Perrault G. The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (1) selective, benzodiazepine receptor ligands. Psychopharmacology (Berlin). 124:1996;245-254.
16. Griebel G., Sanger D.J., Perrault G. The Mouse Defense Test Battery. Evaluation of the effects of non-selective and BZ-1 (1) selective, benzodiazepine receptor ligands Behav. Pharmacol. 7:1996;560-572.
17. Griebel G., Sanger D.J., Perrault G. Genetic differences in the mouse defense test battery. Aggress. Behav. 23:1997;19-31.
18. Judd F.K., Burrows G.D., Marriott P.F., Norman T.R. A short term open clinical trial of clobazam in the treatment of patients with panic attacks. Int. Clin. Psychopharmacol. 4:1989;285-293.
19. Lader M. Benzodiazepines. A risk-benefit profile CNS Drugs. 1:1994;377-387.
20. Langer S.Z., Arbilla S., Tan S., Lloyd K.G., George P., Allen J., Wick A.E. Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry. 23(Suppl. 3):1990;103-107.
21. Martin J.R., Pieri L., Bonetti E.P., Schaffner R., Burkard W.P., Cumin R., Haefely W.E. Ro 16-6028. A novel anxiolytic acting as a partial agonist at the benzodiazepine receptor Pharmacopsychiatry. 21:1988;360-362.
22. Maryanoff B.E., Ho W., McComsey D.F., Reitz A.B., Grous P.P., Nortey S.O., Shank R.P., Dubinsky B., Taylor R.J., Gardocki J.F. Potential anxiolytic agents. Pyrido[1,2- alpha]benzimidazoles. A new structural class of ligands for the benzodiazepine binding site on GABA-A receptors J. Med. Chem. 38:1995;16-20.
23. Stephens D.N., Schneider H.H., Kehr W., Andrews J.S., Rettig K.J., Turski L., Schmiechen R., Turner J.D., Jensen L.H., Petersen E.N. Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J. Pharmacol. Exp. Ther. 253:1990;334-343.
24. Yasumatsu H., Morimoto Y., Yamamoto Y., Takehara S., Fukuda T., Nakao T., Setoguchi M. The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br. J. Pharmacol. 111:1994;1170-1178.